These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3065926)

  • 21. [Role of reactive oxygen species in the bactericidal action of quinolones--inhibitors of DNA gyrase].
    Kotova VIu; Mironov AS; Zavigel'skiĭ GB
    Mol Biol (Mosk); 2014; 48(6):990-8. PubMed ID: 25845240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nalidixic acid on recombination and DNA repair of Escherichia coli K-12 strains.
    Inan S; Kalaycioglu A
    Indian J Exp Biol; 1996 Oct; 34(10):949-53. PubMed ID: 9055644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species].
    Rahal K
    Arch Inst Pasteur Alger; 1992; 58():41-84. PubMed ID: 1309146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1984 May; 13 Suppl B():43-8. PubMed ID: 6234274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinolone action in Escherichia coli cells carrying gyrA and gyrB mutations.
    Herrera G; Aleixandra V; Urios A; Blanco M
    FEMS Microbiol Lett; 1993 Jan; 106(2):187-91. PubMed ID: 8384139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The response of Escherichia coli to ciprofloxacin and norfloxacin.
    Elliott TS; Shelton A; Greenwood D
    J Med Microbiol; 1987 Feb; 23(1):83-8. PubMed ID: 3546699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.
    Piddock LJ; Hall MC; Walters RN
    J Antimicrob Chemother; 1991 Aug; 28(2):185-98. PubMed ID: 1663926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinolone resistance from a transferable plasmid.
    Martínez-Martínez L; Pascual A; Jacoby GA
    Lancet; 1998 Mar; 351(9105):797-9. PubMed ID: 9519952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of urinary isolates of Escherichia coli to cinoxacin.
    Barnham M; Gaya H
    J Antimicrob Chemother; 1979 Jul; 5(4):413-8. PubMed ID: 385579
    [No Abstract]   [Full Text] [Related]  

  • 33. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
    Poiată A; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ; Williams JD
    J Antimicrob Chemother; 1984 May; 13 Suppl B():33-8. PubMed ID: 6234273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.
    Wolfson JS; Hooper DC; Shih DJ; McHugh GL; Swartz MN
    Antimicrob Agents Chemother; 1989 May; 33(5):705-9. PubMed ID: 2665642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resistance to nalidixic acid in tetracycline-resistant mutants of E. coli].
    Khanina MF; Gromova TG; Terekhov AA
    Antibiotiki; 1975; 20(12):1099-104. PubMed ID: 773284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.
    Galante D; Pennucci C; Esposito S; Barba D
    Drugs Exp Clin Res; 1985; 11(5):331-4. PubMed ID: 2941260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Types of spontaneous nalidixic acid resistant mutants of Escherichia coli.
    Kumar S
    Indian J Exp Biol; 1980 Apr; 18(4):341-3. PubMed ID: 6995285
    [No Abstract]   [Full Text] [Related]  

  • 39. [Growing incidence of nalidixic acid resistance and sensitivity to quinolones in Salmonella typhimurium strains isolated from man or animal].
    Heurtin-Le Corre C; Donnio PY; Bonnier M; Travert MF; Lacourt A; Avril JL
    Pathol Biol (Paris); 1998 Oct; 46(8):587-90. PubMed ID: 9871929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nalidixic acid-resistant auxotrophs of Escherichia coli.
    Helling RB; Adams BS
    J Bacteriol; 1970 Nov; 104(2):1027-9. PubMed ID: 4923064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.